Which has better valuation & earnings, ARGX or GMAB?

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 15.21 $1.29B $26.04 39.68 Genmab A/S $3.72B 5.63 $963M $1.27 26.46

Is ARGX or GMAB more profitable?

argenex has a net margin of 32.19% compared to Genmab A/S's net margin of 19.08%. argenex's return on equity of 43.59% beat Genmab A/S's return on equity. Company Net Margins Return on Equity Return on Assets argenex 32.19% 43.59% 36.66% Genmab A/S 19.08% 14.89% 7.73%

Which has stronger earnings and valuation, GMAB or MRNA?

Genmab A/S has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.72B 5.63 $963M $1.27 26.46 Moderna $1.94B 29.89 -$2.82B -$7.99 N/A

Is GMAB or MRNA more profitable?

Genmab A/S has a net margin of 19.08% compared to Moderna's net margin of -141.43%. Genmab A/S's return on equity of 14.89% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 19.08% 14.89% 7.73% Moderna -141.43% -28.30% -19.39%

Which has stronger valuation & earnings, NTRA or GMAB?

Genmab A/S has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 20.51 -$208.16M -$1.36 N/A Genmab A/S $3.72B 5.63 $963M $1.27 26.46

Is NTRA or GMAB more profitable?

Genmab A/S has a net margin of 19.08% compared to Natera's net margin of -7.11%. Genmab A/S's return on equity of 14.89% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Genmab A/S 19.08% 14.89% 7.73%

Genmab A/S (GMAB) Competitors

$33.60 -0.81 (-2.35%)

As of 04:00 PM Eastern

Compare

GMAB vs. REGN, ARGX, MRNA, NTRA, and RVMD

Should you buy Genmab A/S stock or one of its competitors? Genmab A/S's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genmab A/S compare to Regeneron Pharmaceuticals?

Genmab A/S (NASDAQ:GMAB) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 51 more articles in the media than Genmab A/S. MarketBeat recorded 51 mentions for Regeneron Pharmaceuticals and 0 mentions for Genmab A/S. Regeneron Pharmaceuticals' average media sentiment score of 0.66 beat Genmab A/S's score of 0.00 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Genmab A/S	Neutral
Regeneron Pharmaceuticals	Positive

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Genmab A/S's net margin of 19.08%. Genmab A/S's return on equity of 14.89% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Regeneron Pharmaceuticals has higher revenue and earnings than Genmab A/S. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.63	$963M	$1.27	26.46
Regeneron Pharmaceuticals	$14.34B	5.94	$4.50B	$40.46	20.46

Genmab A/S currently has a consensus price target of $39.50, indicating a potential upside of 17.56%. Regeneron Pharmaceuticals has a consensus price target of $800.36, indicating a potential downside of 3.31%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Genmab A/S is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.58

Summary

Regeneron Pharmaceuticals beats Genmab A/S on 11 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to argenex?

argenex (NASDAQ:ARGX) and Genmab A/S (NASDAQ:GMAB) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, argenex had 16 more articles in the media than Genmab A/S. MarketBeat recorded 16 mentions for argenex and 0 mentions for Genmab A/S. argenex's average media sentiment score of 0.51 beat Genmab A/S's score of 0.00 indicating that argenex is being referred to more favorably in the media.

Company	Overall Sentiment
argenex	Positive
Genmab A/S	Neutral

argenex has a net margin of 32.19% compared to Genmab A/S's net margin of 19.08%. argenex's return on equity of 43.59% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Genmab A/S	19.08%	14.89%	7.73%

argenex presently has a consensus price target of $1,158.61, suggesting a potential upside of 12.14%. Genmab A/S has a consensus price target of $39.50, suggesting a potential upside of 17.56%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

60.3% of argenex shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	15.21	$1.29B	$26.04	39.68
Genmab A/S	$3.72B	5.63	$963M	$1.27	26.46

argenex has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Summary

argenex beats Genmab A/S on 15 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Moderna?

Genmab A/S (NASDAQ:GMAB) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Genmab A/S has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.63	$963M	$1.27	26.46
Moderna	$1.94B	29.89	-$2.82B	-$7.99	N/A

Genmab A/S presently has a consensus target price of $39.50, indicating a potential upside of 17.56%. Moderna has a consensus target price of $76.72, indicating a potential downside of 47.29%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, Moderna had 75 more articles in the media than Genmab A/S. MarketBeat recorded 75 mentions for Moderna and 0 mentions for Genmab A/S. Moderna's average media sentiment score of 0.53 beat Genmab A/S's score of 0.00 indicating that Moderna is being referred to more favorably in the news media.

Company	Overall Sentiment
Genmab A/S	Neutral
Moderna	Positive

Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Moderna has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Genmab A/S has a net margin of 19.08% compared to Moderna's net margin of -141.43%. Genmab A/S's return on equity of 14.89% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Moderna	-141.43%	-28.30%	-19.39%

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Genmab A/S beats Moderna on 11 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Natera?

Natera (NASDAQ:NTRA) and Genmab A/S (NASDAQ:GMAB) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Natera presently has a consensus price target of $319.38, indicating a potential downside of 2.68%. Genmab A/S has a consensus price target of $39.50, indicating a potential upside of 17.56%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Genmab A/S has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	20.51	-$208.16M	-$1.36	N/A
Genmab A/S	$3.72B	5.63	$963M	$1.27	26.46

99.9% of Natera shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Natera had 29 more articles in the media than Genmab A/S. MarketBeat recorded 29 mentions for Natera and 0 mentions for Genmab A/S. Natera's average media sentiment score of 1.10 beat Genmab A/S's score of 0.00 indicating that Natera is being referred to more favorably in the media.

Company	Overall Sentiment
Natera	Positive
Genmab A/S	Neutral

Natera has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Genmab A/S has a net margin of 19.08% compared to Natera's net margin of -7.11%. Genmab A/S's return on equity of 14.89% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Genmab A/S	19.08%	14.89%	7.73%

Summary

Genmab A/S beats Natera on 9 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Genmab A/S (NASDAQ:GMAB) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

In the previous week, Revolution Medicines had 33 more articles in the media than Genmab A/S. MarketBeat recorded 33 mentions for Revolution Medicines and 0 mentions for Genmab A/S. Revolution Medicines' average media sentiment score of 0.77 beat Genmab A/S's score of 0.00 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Overall Sentiment
Revolution Medicines	Positive
Genmab A/S	Neutral

Genmab A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,887.37	-$1.13B	-$8.82	N/A
Genmab A/S	$3.72B	5.63	$963M	$1.27	26.46

Genmab A/S has a net margin of 19.08% compared to Revolution Medicines' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Genmab A/S	19.08%	14.89%	7.73%

Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Revolution Medicines presently has a consensus price target of $200.74, indicating a potential downside of 4.42%. Genmab A/S has a consensus price target of $39.50, indicating a potential upside of 17.56%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Revolution Medicines beats Genmab A/S on 9 of the 17 factors compared between the two stocks.

Get Genmab A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMAB vs. The Competition

Export

Metric	Genmab A/S	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$21.46B	$4.03B	$7.28B	$12.92B
Dividend Yield	N/A	3.60%	2.53%	8.90%
P/E Ratio	26.46	12.65	272.42	25.42
Price / Sales	5.63	1,342.84	623.39	95.06
Price / Cash	21.38	107.40	77.39	52.28
Price / Book	3.52	16.15	12.85	6.17
Net Income	$963M	-$22.76M	$3.47B	$349.50M
7 Day Performance	1.11%	1.13%	1.24%	-0.05%
1 Month Performance	15.78%	8.93%	5.81%	0.80%
1 Year Performance	22.72%	52.96%	25.75%	15.62%

Genmab A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMAB Genmab A/S	3.3333 of 5 stars	$33.60 -2.4%	$39.50 +17.6%	+27.1%	$21.46B	$3.72B	26.46	3,029	Analyst Upgrade
REGN Regeneron Pharmaceuticals	4.0684 of 5 stars	$799.08 +0.6%	$800.36 +0.2%	+49.6%	$81.77B	$14.34B	19.75	15,410	Trending News Insider Trade
ARGX argenex	4.2691 of 5 stars	$1,031.66 +0.8%	$1,158.61 +12.3%	+45.9%	$64.01B	$4.25B	39.62	1,863	Analyst Forecast
MRNA Moderna	1.4727 of 5 stars	$140.34 +1.7%	$80.53 -42.6%	+519.0%	$55.09B	$1.94B	N/A	4,700	Trending News Analyst Downgrade Insider Trade Options Volume Analyst Revision Gap Up
NTRA Natera	2.4773 of 5 stars	$321.96 -1.3%	$319.38 -0.8%	+95.6%	$47.03B	$2.31B	N/A	6,140	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMAB) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Competitors

GMAB vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Genmab A/S compare to Regeneron Pharmaceuticals?

Summary

How does Genmab A/S compare to argenex?

Summary

How does Genmab A/S compare to Moderna?

Summary

How does Genmab A/S compare to Natera?

Summary

How does Genmab A/S compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genmab A/S (GMAB) Competitors

GMAB vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Genmab A/S compare to Regeneron Pharmaceuticals?

Do institutionals & insiders believe in GMAB or REGN?

Which has more volatility & risk, GMAB or REGN?

Does the media refer more to GMAB or REGN?

Is GMAB or REGN more profitable?

Which has higher valuation and earnings, GMAB or REGN?

Do analysts recommend GMAB or REGN?

Summary

How does Genmab A/S compare to argenex?

Does the media prefer ARGX or GMAB?

Is ARGX or GMAB more profitable?

Do analysts rate ARGX or GMAB?

Do institutionals and insiders hold more shares of ARGX or GMAB?

Which has better valuation & earnings, ARGX or GMAB?

Which has more volatility & risk, ARGX or GMAB?

Summary

How does Genmab A/S compare to Moderna?

Which has stronger earnings and valuation, GMAB or MRNA?

Do analysts rate GMAB or MRNA?

Does the media refer more to GMAB or MRNA?

Which has more risk and volatility, GMAB or MRNA?

Is GMAB or MRNA more profitable?

Do institutionals & insiders have more ownership in GMAB or MRNA?

Summary

How does Genmab A/S compare to Natera?

Do analysts prefer NTRA or GMAB?

Which has stronger valuation & earnings, NTRA or GMAB?

Do institutionals and insiders have more ownership in NTRA or GMAB?

Does the media favor NTRA or GMAB?

Which has more risk and volatility, NTRA or GMAB?

Is NTRA or GMAB more profitable?

Summary

How does Genmab A/S compare to Revolution Medicines?

Does the media prefer RVMD or GMAB?

Which has stronger valuation & earnings, RVMD or GMAB?

Is RVMD or GMAB more profitable?

Which has more risk & volatility, RVMD or GMAB?

Do analysts prefer RVMD or GMAB?

Do institutionals & insiders believe in RVMD or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools